Skip to main content

Table 2 Prognostic factors for overall survival, progression-free survival, and locoregional failure before and after propensity score-matching

From: Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer

 

Overall survival

Progression-free survival

Locoregional failure

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

Before PSM

Age

(< 58 yrs vs. ≥ 58 yrs)

1.63 (0.86–3.08)

0.133

  

1.14 (0.73–1.78)

0.576

  

1.01 (0.56–1.79)

0.987

  

Sex

(Male vs. Female)

0.46 (0.14–1.50)

0.198

  

0.30 (0.11–0.83)

0.02

0.36 (0.13–0.99)

0.048

0.41 (0.13–1.31)

0.132

0.35 (0.11–1.18)

0.090

Tobacco use

(≤ 10 PY vs. > 10 PY)

0.80 (0.42–1.51)

0.487

  

1.16 (0.74–1.81)

0.523

  

0.70 (0.38–1.28)

0.248

0.49 (0.27–0.91)

0.025

T stage

(T1-2 vs. T3-4)

2.78 (1.48–5.20)

0.001

1.89 (0.95–3.77)

0.070

2.42 (1.52–3.87)

 < 0.001

1.81 (1.09–3.00)

0.022

2.59 (1.42–4.72)

0.002

2.13 (1.09–4.15)

0.027

Clinical N stage

(N0-1 vs. N2-3)

4.20 (2.20–8.02)

 < 0.001

3.25 (1.59–6.61)

0.001

3.18 (1.93–5.26)

 < 0.001

2.79 (1.58–4.91)

 < 0.001

3.19 (1.68–6.08)

 < 0.001

3.70 (1.70–8.05)

0.001

Primary site surgery

(No vs. Yes)

0.41 (0.21–0.80)

0.009

  

0.58 (0.34–0.97)

0.038

  

0.69 (0.34–1.40)

0.303

  

Locoregional radiotherapy

(No vs. Yes)

1.60 (0.62–4.07)

0.329

  

0.82 (0.48–1.39)

0.466

0.57 (0.32–1.00)

0.049

0.45 (0.24–0.83)

0.010

0.26 (0.13–0.51)

 < 0.001

Induction chemotherapy

(No vs. Yes)

1.20 (0.61–2.36)

0.599

  

1.17 (0.73–1.89)

0.506

  

1.39 (0.76–2.55)

0.279

  

After PSM

Age

(< 58 yrs vs. ≥ 58 yrs)

1.35 (0.53–3.44)

0.530

  

0.83 (0.40–1.73)

0.625

  

0.78 (0.31–1.98)

0.605

  

Sex

(Male vs. Female)

0.59 (0.14–2.54)

0.476

  

0.57 (0.17–1.89)

0.359

  

1.04 (0.30–3.58)

0.957

  

Tobacco use

(≤ 10 PY vs. > 10 PY)

1.29 (0.51–3.28)

0.593

  

1.29 (0.61–2.70)

0.507

  

0.59 (0.20–1.80)

0.356

0.37 (0.12–1.16)

0.089

T stage

(T1-2 vs. T3-4)

3.00 (1.21–7.46)

0.018

  

3.18 (1.54–6.58)

0.002

2.09 (0.95–4.59)

0.065

4.83 (1.81–12.89)

0.002

3.76 (1.25–11.35)

0.019

Clinical N stage

(N0-1 vs. N2-3)

5.21 (2.04–13.27)

0.001

5.21 (2.04–13.27)

0.001

4.60 (2.22–9.53)

 < 0.001

3.47 (1.59–7.59)

0.002

4.29 (1.68–10.92)

0.002

2.51 (0.88–7.21)

0.087

Primary site surgery

(No vs. Yes)

0.89 (0.36–2.22)

0.809

  

1.03 (0.50–2.12)

0.929

  

1.34 (0.51–3.47)

0.553

  

Locoregional radiotherapy

(No vs. Yes)

23.10 (0.02–2.82 × 104)

0.387

  

1.28 (0.31–5.40)

0.733

  

0.72 (0.17–3.12)

0.658

  

Induction chemotherapy

(No vs. Yes)

1.99 (0.78–5.06)

0.150

  

1.36 (0.62–2.97)

0.446

  

1.29 (0.46–3.64)

0.628

  
  1. The foreparts of the parentheses were set as the reference groups in the multivariable analysis
  2. HR hazard ratio, CI confidence interval, PSM propensity score-matching, PY pack-years
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us